ARMD.MultS {Surrogate}R Documentation

Data of the Age-Related Macular Degeneration Study with multiple candidate surrogates

Description

These are the data of a clinical trial involving patients suffering from age-related macular degeneration (ARMD), a condition that involves a progressive loss of vision. A total of 181181 patients participated in the trial. Patients' visual acuity was assessed using standardized vision charts. There were two treatment conditions (placebo and interferon-α\alpha). The potential surrogate endpoints are the changes in the visual acuity at 44, 1212, and 2424 weeks after starting treatment. The true endpoint is the change in the visual acuity at 5252 weeks.

Usage

data(ARMD.MultS)

Format

A data.frame with 181181 observations on 66 variables.

Id

The Patient ID.

Diff4

The change in the visual acuity at 44 weeks after starting treatment. This endpoint is a potential surrogate for Diff52.

Diff12

The change in the visual acuity at 1212 weeks after starting treatment. This endpoint is a potential surrogate for Diff52.

Diff24

The change in the visual acuity at 2424 weeks after starting treatment. This endpoint is a potential surrogate for Diff52.

Diff52

The change in the visual acuity at 5252 weeks after starting treatment. This outcome serves as the true endpoint.

Treat

The treatment indicator, coded as 1-1 = placebo and 11 = interferon-α\alpha.


[Package Surrogate version 3.3.0 Index]